1. Academic Validation
  2. Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis

Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis

  • J Cell Biol. 2023 Nov 6;222(11):e202209114. doi: 10.1083/jcb.202209114.
Nisha R Pawar 1 2 3 Marguerite S Buzza 1 2 3 4 Nadire Duru 1 2 Amando A Strong 1 Toni M Antalis 1 2 3 4
Affiliations

Affiliations

  • 1 Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, USA.
  • 2 Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • 3 Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
  • 4 Research and Development Service, VA Maryland Health Care System , Baltimore, MD, USA.
Abstract

The transmembrane serine protease matriptase is a key regulator of both barrier-disruptive and protective epithelial cell-cell interactions. Elevated matriptase is a consistent feature of epithelial ovarian cancers (OvCa), where multicellular spheroids shed from the primary tumor into the peritoneal cavity are critical drivers of metastasis. Dynamic cell-to-cell adhesive contacts are required for spheroid formation and maintenance. Here, we show that overactive matriptase, reflected in an increased ratio of matriptase to its inhibitor hepatocyte growth factor activator inhibitor 1 (HAI-1), disrupts cell-cell contacts to produce loose prometastatic spheroids that display increased mesothelial cell adhesion and submesothelial invasion. We show that these activities are dependent on the matriptase activation of a protease-activated receptor-2 (PAR-2) signaling pathway involving PI3K/Akt and MMP9-induced disruption of cell-cell adhesion by the release of the soluble E-cadherin ectodomain. These data reveal a novel pathological connection between matriptase activation of PAR-2 and disruption of cell-cell adhesion, and support the clinical investigation of this signaling axis as a therapeutic strategy for aggressive metastatic OvCa.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12354
    99.59%, MMP2/9 Inhibitor
    MMP
  • HY-103482
    99.39%, MMP-9 Inhibitor
    MMP